NEU.INH_VIP.develop_niche: Studies — page 12
How association tiers are defined — cell–trait and gene–trait
SCREATE tier definitions supplied by the atlas curator. This methods note explains the prepared classifications; it does not recompute or change any report scores or tiers.
Cell–trait tiers
- Cell–trait links
- Identify cell types whose regulatory activity is associated with a trait’s genetic signal.
- Required for Specific or Relevant
- The ICE-CREAM score derived from the mean metacell Z score must be ≥ 5.39, with BOTH nominal and adjusted ICE-CREAM P values ≤ 0.05.
- Specific (Tier 1)
- Also meets all cell-set enrichment analysis (CSEA) criteria in at least one tested comparison: nominal P ≤ 0.05 AND adjusted P ≤ 0.05 AND normalized enrichment score (NES) ≥ 1, all in that comparison. This indicates that trait-associated activity is concentrated in this cell type relative to the tested background.
- Relevant (Tier 2)
- Meets the ICE-CREAM requirements but not the additional CSEA criteria. The cell type may share trait-associated activity with other cell types.
- Interpretation and report values
- CSEA is cell-set enrichment analysis, analogous to gene-set enrichment analysis but using sets of cells along a ranked list of ICE-CREAM scores. The eligibility score derived from the mean metacell Z score is not the displayed mean IC score. Do not infer a tier from the displayed mean, its descriptive Significance column, or a single CSEA summary value. Reports preserve prepared tiers; Other means an available association outside Specific/Relevant, and unavailable is not zero or proof of biological irrelevance.
- Meta traits and individual traits
- Use the prepared tier for the exact meta trait or individual trait. A meta trait’s Best child CSEA FDR is the lowest available child FDR, not a combined or meta-trait significance test. Its displayed mean child NES is descriptive, not a new CSEA test. These summaries must not be used to reconstruct or override the meta-trait tier.
Gene–trait priorities (variant–tCRE–gene evidence)
- Variant–tCRE–gene links
- Candidate variants connect to genes through overlapping promoters or distal transcribed cis-regulatory elements (tCREs) linked to gene promoters by the Activity-by-Contact (ABC) model.
- Required genetic support
- The variant belongs to a purity-passing SuSiE credible set OR qualifies for Borzoi rescue. Borzoi rescue requires BOTH a variant-causality score ≥ 0.3 AND linkage disequilibrium with the lead variant of r² ≥ 0.2.
- Required cellular support
- The overlapping promoter has positive tCRE activity OR the distal element has a passing cell-specific ABC link to the gene, in a Specific or Relevant cell subtype (L1S) or fine-grained state (L2). BOTH genetic and cellular support are required for High or Medium priority.
- High priority
- Among records meeting both minimum requirements, High requires a genetic score ≥ 0.5 AND a Layer 1 correlation > 0.3 between tCRE activity and the trait’s cellular profile across cell subtypes.
- Medium priority
- Meets both minimum requirements but not one or both additional High thresholds. The genetic score is the higher of the SuSiE posterior inclusion probability (PIP) and the Borzoi variant-causality score.
- Same-record evidence and aggregation
- Each priority requires genetic and cellular evidence supporting the SAME variant–tCRE–gene record. Do not combine thresholds or evidence from different records to create a qualifying link. A gene receives the highest priority observed among its supporting records. A tCRE summary uses supporting records for that exact tCRE, not every trait of its linked genes. Separately displayed aggregate scores do not relax the same-record rule.
- Limits of interpretation
- A priority is candidate-association evidence, not proof of a causal variant, causal gene, causal cell type or treatment efficacy. Missing evidence is unavailable, not zero. MAGMA −log10(P), displayed credibility scores, cellular-context scores and G/C tier codes must not be substituted for these eligibility tests; use the provided records and their documented fields.
State · 122 full-atlas cells · all tissues.
Marker genes and cell annotation · Open this population in Cell Browser →
ICE-CREAM (IC) is −log10(P) from a permutation test. An IC score of 3 corresponds to an unadjusted P value of 0.001; 5.5 is the multiple-testing-corrected significance threshold across all metacells. The Significance categories are Significant for IC > 5.5, Nominal for 3 ≤ IC ≤ 5.5, and Nonsignificant for IC < 3. These reports display mean IC scores across full-atlas populations, not the UMAP sample. The categories apply to the displayed scores: a cell-group mean or an average across individual traits is descriptive and is not itself a newly tested P value or a new multiple-testing correction. All scores are retained. Enrichment is not proof of causality or treatment efficacy.
Rows 11,001–12,000 of 12,313; ranked by score descending. Equal values use name/identifier order.
| # | Trait / study | Individual trait ID | Mean IC score |
|---|---|---|---|
| 11001 | LY6D/PLA2G10 ratio | GCST90315345 | 7.40e-05 |
| 11002 | CLEC1B/ITGB5 ratio | GCST90314094 | 7.34e-05 |
| 11003 | Omega-3 fatty acids to total fatty acids percentage | GCST90502466 | 7.33e-05 |
| 11004 | GGH/INHBC ratio | GCST90314928 | 7.28e-05 |
| 11005 | Psoriasis | FING00001222 | 7.27e-05 |
| 11006 | Peritonsillar abscess | FING00001160 | 7.26e-05 |
| 11007 | ALB levels | GCST90475103 | 7.26e-05 |
| 11008 | CRTAM levels | GCST90468871 | 7.26e-05 |
| 11009 | Sphingomyelin_42:2_[M+H]1+ levels | GCST90060403 | 7.25e-05 |
| 11010 | Posterior thigh muscle fat infiltration percentage | GCST90267355 | 7.23e-05 |
| 11011 | NFKB1 levels | GCST90470037 | 7.22e-05 |
| 11012 | EIF2AK2 levels | GCST90469091 | 7.22e-05 |
| 11013 | mean platelet volume (MPV, maximum, inv-norm transformed) | GCST90475517 | 7.21e-05 |
| 11014 | DKK1/SDC4 ratio | GCST90314479 | 7.20e-05 |
| 11015 | Glycoprotein acetyls levels | GCST90497320 | 7.20e-05 |
| 11016 | FKBP4/RWDD1 ratio | GCST90314840 | 7.17e-05 |
| 11017 | Nontoxic multinodular goiter | endocrine/metabolic | UKBB00000528 | 7.17e-05 |
| 11018 | Crohn's disease | GCST004132 | 7.15e-05 |
| 11019 | Migraine, single triptan purchase ok & required. ICD-code if available is included | FING00000824 | 7.12e-05 |
| 11020 | ALCAM/LRRC25 ratio | GCST90313239 | 7.11e-05 |
| 11021 | CD69/PLXNB3 ratio | GCST90313881 | 7.10e-05 |
| 11022 | SNAP23 levels | GCST90470690 | 7.05e-05 |
| 11023 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T488 | ECGU000488 | 7.03e-05 |
| 11024 | Phospholipids to Total Lipids in Small HDL percentage | GCST90499505 | 7.01e-05 |
| 11025 | CD84/SDC4 ratio | GCST90313916 | 7.01e-05 |
| 11026 | ENG/TNFRSF10C ratio | GCST90314650 | 7.00e-05 |
| 11027 | Cerebral amyloid angiopathy | FING00000262 | 6.94e-05 |
| 11028 | ACRBP levels | GCST90468205 | 6.92e-05 |
| 11029 | Saturated fatty acids levels | GCST90502670 | 6.91e-05 |
| 11030 | F2R/PDGFB ratio | GCST90314733 | 6.91e-05 |
| 11031 | MMP1 levels | GCST90469919 | 6.91e-05 |
| 11032 | CXCL5/PLXNA4 ratio | GCST90314351 | 6.87e-05 |
| 11033 | Mean platelet volume during first trimester of pregnancy | GCST90302229 | 6.86e-05 |
| 11034 | CLMP levels | GCST90468783 | 6.85e-05 |
| 11035 | NID1/SORT1 ratio | GCST90315542 | 6.83e-05 |
| 11036 | CD244 levels | GCST90274771 | 6.81e-05 |
| 11037 | IRAK4 levels | GCST90469628 | 6.76e-05 |
| 11038 | CANT1 levels | GCST90468536 | 6.74e-05 |
| 11039 | SF3B4 levels | GCST90470609 | 6.73e-05 |
| 11040 | Carnitine levels | GCST90239991 | 6.72e-05 |
| 11041 | SPON1 levels | GCST90470731 | 6.69e-05 |
| 11042 | ASPSCR1 levels | GCST90468378 | 6.68e-05 |
| 11043 | CST3/EFEMP1 ratio | GCST90314292 | 6.67e-05 |
| 11044 | GAL levels | GCST90469300 | 6.67e-05 |
| 11045 | HYOU1/TGFBR3 ratio | GCST90315105 | 6.66e-05 |
| 11046 | Monocyte percentage of white cells | GCST90002394 | 6.64e-05 |
| 11047 | ITGA5/SELE ratio | GCST90315205 | 6.64e-05 |
| 11048 | Mean platelet volume at delivery | GCST90302232 | 6.63e-05 |
| 11049 | FLT3LG levels | GCST90274791 | 6.63e-05 |
| 11050 | GGACT levels | GCST90469333 | 6.60e-05 |
| 11051 | ESYT2 levels | GCST90469156 | 6.59e-05 |
| 11052 | CCNE1 levels | GCST90468593 | 6.58e-05 |
| 11053 | CDNF levels | GCST90468686 | 6.56e-05 |
| 11054 | FGFBP2 levels | GCST90469231 | 6.55e-05 |
| 11055 | CMC1 levels | GCST90468794 | 6.55e-05 |
| 11056 | SFTPA1 levels | GCST90470612 | 6.54e-05 |
| 11057 | High light scatter reticulocyte count | GCST004611 | 6.54e-05 |
| 11058 | CD38/IL12A_IL12B ratio | GCST90313808 | 6.54e-05 |
| 11059 | FAM3C/NECTIN2 ratio | GCST90314781 | 6.49e-05 |
| 11060 | Platelet distribution width | Blood count | UKBB00000648 | 6.48e-05 |
| 11061 | AFP levels | GCST90278615 | 6.46e-05 |
| 11062 | SERPINB1 levels | GCST90470589 | 6.41e-05 |
| 11063 | EREG/MPI ratio | GCST90314705 | 6.40e-05 |
| 11064 | TREH levels | GCST90470959 | 6.36e-05 |
| 11065 | IDP dMRI TBSS L1 Cingulum cingulate gyrus R | GCST90004109 | 6.36e-05 |
| 11066 | Omega-3 fatty acids to total fatty acids percentage | GCST90502462 | 6.36e-05 |
| 11067 | Free cholesterol to total lipids ratio in large VLDL | GCST90092873 | 6.33e-05 |
| 11068 | Electrocardiogram morphology (amplitude at temporal datapoints) adjusted, T109 | ECGA000109 | 6.32e-05 |
| 11069 | EFNA1 levels | GCST90469080 | 6.30e-05 |
| 11070 | CD300C levels | GCST90468620 | 6.29e-05 |
| 11071 | MRC1 levels | GCST90469939 | 6.26e-05 |
| 11072 | ANGPTL3/TFPI ratio | GCST90313270 | 6.23e-05 |
| 11073 | SKAP2 levels | GCST90470646 | 6.22e-05 |
| 11074 | KLRB1/KLRD1 ratio | GCST90315260 | 6.22e-05 |
| 11075 | POF1B levels | GCST90470281 | 6.19e-05 |
| 11076 | SULT2A1 levels | GCST90470782 | 6.19e-05 |
| 11077 | EPHB6 levels | GCST90469133 | 6.17e-05 |
| 11078 | Heel bone mineral density (BMD) (right) | Bone-densitometry of heel | UKBB00000314 | 6.16e-05 |
| 11079 | DAPP1/ITGB1BP2 ratio | GCST90314388 | 6.14e-05 |
| 11080 | APOA1 levels | GCST90468331 | 6.14e-05 |
| 11081 | NRGN levels | GCST90470083 | 6.11e-05 |
| 11082 | Red cell distribution width | GCST90002404 | 6.10e-05 |
| 11083 | AXL/VCAM1 ratio | GCST90313423 | 6.08e-05 |
| 11084 | LATS1 levels | GCST90469740 | 6.08e-05 |
| 11085 | CAPG levels | GCST90468537 | 6.05e-05 |
| 11086 | Free Cholesterol to Total Lipids in Small VLDL percentage | GCST90499832 | 6.03e-05 |
| 11087 | MTIF3 levels | GCST90469957 | 6.02e-05 |
| 11088 | CD27/TNFRSF9 ratio | GCST90313778 | 6.01e-05 |
| 11089 | Uterine fibroids | GCST90018714 | 6.00e-05 |
| 11090 | GMPR2 levels | GCST90469367 | 6.00e-05 |
| 11091 | YES1 levels | GCST90471088 | 5.99e-05 |
| 11092 | Takes medication for Skin condition (ex. Eczema, Psoriasis)? | GCST90475275 | 5.99e-05 |
| 11093 | Seborrheic dermatitis (PheCode 690.1) | GCST90476171 | 5.97e-05 |
| 11094 | RTN4IP1 levels | GCST90470507 | 5.95e-05 |
| 11095 | Mean arterial pressure, manual reading | Cardiovascular measurement | UKBB00000441 | 5.92e-05 |
| 11096 | Free Cholesterol to Total Lipids in Very Small VLDL percentage | GCST90500791 | 5.92e-05 |
| 11097 | ALOX15B levels | GCST90617547 | 5.92e-05 |
| 11098 | Cholesterol in Small HDL | GCST90499358 | 5.91e-05 |
| 11099 | DDR1/SFTPD ratio | GCST90314443 | 5.89e-05 |
| 11100 | GM3 ganglioside (d18:1/24:0) levels | GCST90025340 | 5.89e-05 |
| 11101 | LAT levels | GCST90469741 | 5.85e-05 |
| 11102 | DKK1/VEGFA ratio | GCST90314483 | 5.85e-05 |
| 11103 | CRELD2/TXNDC5 ratio | GCST90314259 | 5.83e-05 |
| 11104 | Triglycerides to Total Lipids in Very Small VLDL percentage | GCST90500886 | 5.81e-05 |
| 11105 | Bone density (confirmatory factor analysis Factor 19) | GCST90309353 | 5.76e-05 |
| 11106 | DKK1/PDGFA ratio | GCST90314475 | 5.75e-05 |
| 11107 | ITGA2 levels | GCST90469634 | 5.72e-05 |
| 11108 | TGFBR2/THBD ratio | GCST90315916 | 5.72e-05 |
| 11109 | TINAGL1 levels | GCST90470873 | 5.71e-05 |
| 11110 | SCGB3A2 levels | GCST90470543 | 5.69e-05 |
| 11111 | Triacylglycerol_52:2_[M+NH4]1+ levels | GCST90060511 | 5.69e-05 |
| 11112 | PI16 levels | GCST90470229 | 5.69e-05 |
| 11113 | VWA1 levels | GCST90471061 | 5.68e-05 |
| 11114 | HHIP levels | GCST90617097 | 5.61e-05 |
| 11115 | white blood cell count (WBC, mean, inv-norm transformed) | GCST90476454 | 5.60e-05 |
| 11116 | Athlete's foot (PheCode 110.12) | GCST90475563 | 5.57e-05 |
| 11117 | HDL x depression interaction (2df test) | GCST90570667 | 5.56e-05 |
| 11118 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502411 | 5.56e-05 |
| 11119 | Lysophosphatidylcholine (24:0) [sn2] levels | GCST90025426 | 5.54e-05 |
| 11120 | CCN2/SERPINB1 ratio | GCST90313715 | 5.53e-05 |
| 11121 | SCG3 levels | GCST90470539 | 5.53e-05 |
| 11122 | red blood cell count (RBC, mean, inv-norm transformed) | GCST90476347 | 5.52e-05 |
| 11123 | SOD2 levels | GCST90470705 | 5.51e-05 |
| 11124 | IL1R1 levels | GCST90469571 | 5.50e-05 |
| 11125 | ARHGEF12/IRAK4 ratio | GCST90313350 | 5.48e-05 |
| 11126 | CD74/LILRB4 ratio | GCST90313894 | 5.46e-05 |
| 11127 | TIMM8A levels | GCST90470868 | 5.46e-05 |
| 11128 | platelet count (minimum, inv-norm transformed) | GCST90476302 | 5.44e-05 |
| 11129 | CD69/CDKN2D ratio | GCST90313866 | 5.44e-05 |
| 11130 | Triglycerides in IDL | GCST90497661 | 5.43e-05 |
| 11131 | TACSTD2 levels | GCST90470798 | 5.41e-05 |
| 11132 | CD300C/GOLM2 ratio | GCST90313788 | 5.41e-05 |
| 11133 | CCN3/COL6A3 ratio | GCST90313720 | 5.37e-05 |
| 11134 | ST6GAL1 levels | GCST90470753 | 5.36e-05 |
| 11135 | LAMA4/PDGFB ratio | GCST90315273 | 5.35e-05 |
| 11136 | IFNG levels | GCST90469515 | 5.35e-05 |
| 11137 | Minimum carotid IMT (intima-medial thickness) at 210 degrees | Carotid ultrasound | UKBB00000477 | 5.33e-05 |
| 11138 | FKBP5 levels | GCST90469244 | 5.32e-05 |
| 11139 | CD300C/MANSC1 ratio | GCST90313791 | 5.32e-05 |
| 11140 | CXCL17 levels | GCST90468929 | 5.31e-05 |
| 11141 | ATF6 levels | GCST90240816 | 5.29e-05 |
| 11142 | Cholesterol in IDL | GCST90497495 | 5.29e-05 |
| 11143 | CLEC1B/LBR ratio | GCST90314095 | 5.29e-05 |
| 11144 | CILP levels | GCST90468754 | 5.27e-05 |
| 11145 | Monocyte count | GCST90018747 | 5.27e-05 |
| 11146 | Platelet crit (UKB data field 30090) | GCST90468096 | 5.27e-05 |
| 11147 | PSAP levels | GCST90470351 | 5.27e-05 |
| 11148 | SMOC1 levels | GCST90470682 | 5.27e-05 |
| 11149 | aparc-a2009s lh volume G-front-inf-Opercular | GCST90002936 | 5.27e-05 |
| 11150 | DTI TBSS MD Superior corona radiata R | GCST90384596 | 5.25e-05 |
| 11151 | Cholesterol levels in very large HDL | GCST90500310 | 5.24e-05 |
| 11152 | B4GALT1 levels | GCST90468412 | 5.23e-05 |
| 11153 | PLIN3/TYMP ratio | GCST90315678 | 5.22e-05 |
| 11154 | STAMBP/WWP2 ratio | GCST90315888 | 5.22e-05 |
| 11155 | Concentration of small VLDL particles | GCST90499856 | 5.20e-05 |
| 11156 | IL12RB1 levels | GCST90469550 | 5.19e-05 |
| 11157 | PEAR1/SPINT2 ratio | GCST90315644 | 5.19e-05 |
| 11158 | CDSN/KLK8 ratio | GCST90313996 | 5.19e-05 |
| 11159 | GFER levels | GCST90469326 | 5.19e-05 |
| 11160 | CSF1/LTBR ratio | GCST90314287 | 5.17e-05 |
| 11161 | PRELP levels | GCST90470321 | 5.13e-05 |
| 11162 | WASHC3 levels | GCST90471069 | 5.12e-05 |
| 11163 | Other contact dermatitis | FING00000990 | 5.11e-05 |
| 11164 | Fracture of hand or wrist (PheCode 804) | GCST90476281 | 5.11e-05 |
| 11165 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 107) | GCST90320670 | 5.10e-05 |
| 11166 | AmygNuclei lh volume Medial-nucleus | GCST90002653 | 5.08e-05 |
| 11167 | PLSCR3 levels | GCST90470261 | 5.07e-05 |
| 11168 | RAB27B levels | GCST90470405 | 5.06e-05 |
| 11169 | Erythematosquamous dermatosis (PheCode 690) | GCST90476170 | 5.05e-05 |
| 11170 | TNFRSF1B levels | GCST90012026 | 5.05e-05 |
| 11171 | CDCP1/MSR1 ratio | GCST90313938 | 5.05e-05 |
| 11172 | BACH1/NFATC1 ratio | GCST90313444 | 5.04e-05 |
| 11173 | Phosphatidylcholine-O_40:5_[M+H]1+/Phosphatidylcholine-P_40:4_[M+H]1+ levels | GCST90060423 | 5.02e-05 |
| 11174 | CD69 levels | GCST90468643 | 5.02e-05 |
| 11175 | SBSN levels | GCST90470531 | 5.01e-05 |
| 11176 | EPHA4 levels | GCST90469131 | 5.00e-05 |
| 11177 | Mosaic chromosomal alteration of the Y chromosome | GCST90165289 | 4.97e-05 |
| 11178 | TNFAIP8L2 levels | GCST90470897 | 4.96e-05 |
| 11179 | CD300E levels | GCST90468621 | 4.95e-05 |
| 11180 | Severe autoimmune type 2 diabetes | GCST90026412 | 4.92e-05 |
| 11181 | Glycoprotein acetyls levels (UKB data field 23480) | GCST90269577 | 4.90e-05 |
| 11182 | CCL11/CCL13 ratio | GCST90313671 | 4.88e-05 |
| 11183 | PTGES2 levels | GCST90470369 | 4.86e-05 |
| 11184 | Monocyte percentage (UKB data field 30190) | GCST90468091 | 4.83e-05 |
| 11185 | FUT3_FUT5/LILRA2 ratio | GCST90314889 | 4.83e-05 |
| 11186 | Triacylglycerol_56:6_[M+NH4]1+ levels | GCST90060553 | 4.80e-05 |
| 11187 | IL16/NADK ratio | GCST90315152 | 4.79e-05 |
| 11188 | ALKBH3 levels | GCST90619095 | 4.79e-05 |
| 11189 | Fluid intelligence score decline (log-difference score) | GCST90565852 | 4.75e-05 |
| 11190 | Current employment status - Doing unpaid or voluntary work | Employment | UKBB00000157 | 4.74e-05 |
| 11191 | Total bilirubin levels | GCST90278643 | 4.72e-05 |
| 11192 | White blood cell count | GCST90002375 | 4.71e-05 |
| 11193 | SEC31A levels | GCST90470563 | 4.70e-05 |
| 11194 | Linoleic acid to total fatty acids percentage | GCST90502321 | 4.69e-05 |
| 11195 | Gastric cancer | GCST90018629 | 4.67e-05 |
| 11196 | SCARA5 levels | GCST90470533 | 4.65e-05 |
| 11197 | Crohn's disease | GCST90446793 | 4.63e-05 |
| 11198 | CTSF levels | GCST90468912 | 4.63e-05 |
| 11199 | ADAMTS16 levels | GCST90468224 | 4.61e-05 |
| 11200 | NRP2 levels | GCST90470086 | 4.58e-05 |
| 11201 | X-25371 levels | GCST90200656 | 4.58e-05 |
| 11202 | Peptic ulcer disease | GCST90270926 | 4.57e-05 |
| 11203 | EREG/HBEGF ratio | GCST90314702 | 4.57e-05 |
| 11204 | TGFBI/VASN ratio | GCST90315915 | 4.56e-05 |
| 11205 | TREML1 levels | GCST90470961 | 4.52e-05 |
| 11206 | Serum urea levels | GCST90025991 | 4.49e-05 |
| 11207 | Free cholesterol to total lipids in very large HDL percentage (UKB data field 23632) | GCST90269729 | 4.48e-05 |
| 11208 | TNFRSF13B levels | GCST90470905 | 4.48e-05 |
| 11209 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T138 | ECGU000138 | 4.45e-05 |
| 11210 | SLC9A3R1 levels | GCST90470665 | 4.43e-05 |
| 11211 | GASK1A levels | GCST90469306 | 4.43e-05 |
| 11212 | PDGFC levels | GCST90470190 | 4.41e-05 |
| 11213 | Seronegative rheumatoid arthritis | FING00001296 | 4.41e-05 |
| 11214 | NOTCH3 levels | GCST90470067 | 4.41e-05 |
| 11215 | T1 FreeSurfer a2009s lh S postcentral area | GCST90384734 | 4.40e-05 |
| 11216 | 3-(4-hydroxyphenyl)lactate levels | GCST90243575 | 4.39e-05 |
| 11217 | GALNT10/TNFSF12 ratio | GCST90314916 | 4.33e-05 |
| 11218 | CD46/NID1 ratio | GCST90313833 | 4.33e-05 |
| 11219 | CD244 levels | GCST90468611 | 4.32e-05 |
| 11220 | GART levels | GCST90469303 | 4.30e-05 |
| 11221 | Disorders of skin appendages | FING00000460 | 4.28e-05 |
| 11222 | Total cholesterol levels | GCST90278644 | 4.27e-05 |
| 11223 | MARS1 levels | GCST90469862 | 4.27e-05 |
| 11224 | Fibromuscular dysplasia | GCST90026612 | 4.27e-05 |
| 11225 | AmygNuclei lh volume Accessory-Basal-nucleus | GCST90002650 | 4.27e-05 |
| 11226 | CD28 levels | GCST90468616 | 4.26e-05 |
| 11227 | CD160/CXCL16 ratio | GCST90313728 | 4.26e-05 |
| 11228 | MANSC1 levels | GCST90469847 | 4.26e-05 |
| 11229 | Acetoacetate levels | GCST90092804 | 4.25e-05 |
| 11230 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T109 | ECGU000109 | 4.24e-05 |
| 11231 | PLB1 levels | GCST90470253 | 4.23e-05 |
| 11232 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T113 | ECGU000113 | 4.23e-05 |
| 11233 | Clonal hematopoiesis (overall) | GCST90435353 | 4.21e-05 |
| 11234 | ALCAM/MSR1 ratio | GCST90313240 | 4.19e-05 |
| 11235 | CETN2 levels | GCST90468721 | 4.18e-05 |
| 11236 | Diseases of external ear | FING00000424 | 4.18e-05 |
| 11237 | high density lipoprotein cholesterol (HDLC, minimm, inv-norm transformed) | GCST90475356 | 4.18e-05 |
| 11238 | ELN levels | GCST90469103 | 4.17e-05 |
| 11239 | CLEC4G/KDR ratio | GCST90314118 | 4.17e-05 |
| 11240 | Right ventricular stroke volume | GCST90268122 | 4.13e-05 |
| 11241 | Stroke, excluding SAH | FING00001337 | 4.13e-05 |
| 11242 | DTI TBSS MD Posterior corona radiata L | GCST90384599 | 4.11e-05 |
| 11243 | PECAM1/SOD2 ratio | GCST90315647 | 4.11e-05 |
| 11244 | Heel quantitative ultrasound index (QUI), direct entry (right) | Bone-densitometry of heel | UKBB00000323 | 4.11e-05 |
| 11245 | Heel bone mineral density (BMD) T-score, automated (right) | Bone-densitometry of heel | UKBB00000317 | 4.11e-05 |
| 11246 | DAB2 levels | GCST90468942 | 4.11e-05 |
| 11247 | GCC1 levels | GCST90469315 | 4.08e-05 |
| 11248 | Biliary cirrhosis, NAS | FING00000213 | 4.07e-05 |
| 11249 | GPC1 levels | GCST90469386 | 4.04e-05 |
| 11250 | rfMRI connectivity (ICA100 edge 383) | GCST90005236 | 4.03e-05 |
| 11251 | F9/RARRES2 ratio | GCST90314749 | 4.01e-05 |
| 11252 | Omega-6 fatty acids to total fatty acids percentage (UKB data field 23452) | GCST90269549 | 4.00e-05 |
| 11253 | Total Dihexosylceramide levels | GCST90025193 | 4.00e-05 |
| 11254 | CRADD levels | GCST90468854 | 3.99e-05 |
| 11255 | CA12 levels | GCST90468507 | 3.98e-05 |
| 11256 | PILRB levels | GCST90470237 | 3.97e-05 |
| 11257 | NFATC1 levels | GCST90470033 | 3.96e-05 |
| 11258 | NAAA/SMPD1 ratio | GCST90315510 | 3.96e-05 |
| 11259 | Omega-3 fatty acid levels | GCST90502440 | 3.94e-05 |
| 11260 | monocyte (fraction, maximum, inv-norm transformed) | GCST90475508 | 3.94e-05 |
| 11261 | PPME1/PSMD9 ratio | GCST90315705 | 3.93e-05 |
| 11262 | EREG levels | GCST90469145 | 3.92e-05 |
| 11263 | aseg lh volume Hippocampus | GCST90002624 | 3.92e-05 |
| 11264 | CST1 levels | GCST90468893 | 3.91e-05 |
| 11265 | EIF4G1/FOXO1 ratio | GCST90314634 | 3.91e-05 |
| 11266 | SORCS2 levels | GCST90470708 | 3.89e-05 |
| 11267 | SERPINB9 levels | GCST90470593 | 3.89e-05 |
| 11268 | SIRPB1 levels | GCST90470640 | 3.89e-05 |
| 11269 | CD48 levels | GCST90425676 | 3.88e-05 |
| 11270 | CD74/DLL1 ratio | GCST90313891 | 3.86e-05 |
| 11271 | ANPEP/DPP4 ratio | GCST90313273 | 3.86e-05 |
| 11272 | BSG/TNFRSF4 ratio | GCST90313536 | 3.86e-05 |
| 11273 | Abdominal hernia (PheCode 550) | GCST90476059 | 3.85e-05 |
| 11274 | BCR/NFATC1 ratio | GCST90313496 | 3.85e-05 |
| 11275 | CHCHD10 levels | GCST90468738 | 3.85e-05 |
| 11276 | ELAC1 levels | GCST90469101 | 3.84e-05 |
| 11277 | Charcot foot | FING00000268 | 3.84e-05 |
| 11278 | C8 Carnitine levels in chronic kidney disease | GCST90257680 | 3.83e-05 |
| 11279 | GFRA1 levels | GCST90469328 | 3.83e-05 |
| 11280 | CRKL levels | GCST90468867 | 3.82e-05 |
| 11281 | Alzheimer's disease or family history of Alzheimer's disease | GCST90012877 | 3.82e-05 |
| 11282 | PSRC1/SORT1 ratio | GCST90315742 | 3.82e-05 |
| 11283 | SERPINB1/SERPINB9 ratio | GCST90315827 | 3.81e-05 |
| 11284 | CCL23 levels | GCST90468575 | 3.80e-05 |
| 11285 | Heel bone mineral density (BMD) (left) | Bone-densitometry of heel | UKBB00000313 | 3.79e-05 |
| 11286 | RAP1A levels | GCST90470425 | 3.79e-05 |
| 11287 | LILRB1 levels | GCST90469776 | 3.79e-05 |
| 11288 | LTBP2 levels | GCST90469814 | 3.79e-05 |
| 11289 | CD209 levels | GCST90468608 | 3.76e-05 |
| 11290 | Right-hemisphere visual network to pallidum white-matter structural connectivity | GCST90302784 | 3.76e-05 |
| 11291 | Diseases of vocal cords and larynx+other diseases of upper respiratory tract, no elsewhere classified | FING00000432 | 3.76e-05 |
| 11292 | STX8 levels | GCST90470776 | 3.76e-05 |
| 11293 | CX3CL1/PODXL2 ratio | GCST90314326 | 3.74e-05 |
| 11294 | Blood clot / pulmonary embolism / deep vein thrombosis (DVT) | GCST90475209 | 3.70e-05 |
| 11295 | aseg rh intensity Caudate | GCST90003783 | 3.70e-05 |
| 11296 | DSG2 levels | GCST90469042 | 3.69e-05 |
| 11297 | MILR1 levels | GCST90469907 | 3.66e-05 |
| 11298 | ANGPTL4 levels | GCST90468305 | 3.65e-05 |
| 11299 | S100P levels | GCST90470520 | 3.65e-05 |
| 11300 | ADH4/KYNU ratio | GCST90313193 | 3.63e-05 |
| 11301 | SIGLEC6 levels | GCST90470634 | 3.63e-05 |
| 11302 | REST UKBBICA NODEamps25 0003 | GCST90385486 | 3.62e-05 |
| 11303 | FSHB levels | GCST90469270 | 3.62e-05 |
| 11304 | NID1 levels | GCST90470047 | 3.62e-05 |
| 11305 | wg lh intensity-contrast temporalpole | GCST90003824 | 3.61e-05 |
| 11306 | DKK1/VASH1 ratio | GCST90314482 | 3.56e-05 |
| 11307 | Crohn's disease of large intestine | FING00000368 | 3.56e-05 |
| 11308 | CRKL/MANF ratio | GCST90314269 | 3.54e-05 |
| 11309 | Non-allergic asthma (mode) (more control exclusions) | FING00000869 | 3.53e-05 |
| 11310 | Reticulocyte count | GCST90002405 | 3.53e-05 |
| 11311 | CD69/CLEC1B ratio | GCST90313869 | 3.53e-05 |
| 11312 | Phosphatidylcholine-O_38:5_[M+H]1+/Phosphatidylcholine-P_38:4_[M+H]1+ levels | GCST90060375 | 3.53e-05 |
| 11313 | HPCAL1 levels | GCST90469471 | 3.53e-05 |
| 11314 | SPRY2 levels | GCST90470738 | 3.52e-05 |
| 11315 | ADGRE1 levels | GCST90468236 | 3.50e-05 |
| 11316 | SLAMF8 levels | GCST90470652 | 3.50e-05 |
| 11317 | MANSC1/PODXL2 ratio | GCST90315371 | 3.49e-05 |
| 11318 | PLG levels | GCST90470257 | 3.49e-05 |
| 11319 | GP1BA/HBEGF ratio | GCST90314956 | 3.48e-05 |
| 11320 | MMP9/OLR1 ratio | GCST90315467 | 3.48e-05 |
| 11321 | IL17D levels | GCST90469560 | 3.47e-05 |
| 11322 | MSR1/TNFRSF21 ratio | GCST90315494 | 3.46e-05 |
| 11323 | Phospholipids in very large HDL (UKB data field 23553) | GCST90269650 | 3.46e-05 |
| 11324 | CLEC4C levels | GCST90468772 | 3.46e-05 |
| 11325 | FOLH1 levels | GCST90427192 | 3.46e-05 |
| 11326 | SLC27A4 levels | GCST90470657 | 3.45e-05 |
| 11327 | CLUL1 levels | GCST90468792 | 3.42e-05 |
| 11328 | Omega-3 fatty acid levels | GCST90502436 | 3.42e-05 |
| 11329 | CD6 levels | GCST90468644 | 3.40e-05 |
| 11330 | IL12B levels | GCST90469549 | 3.39e-05 |
| 11331 | CD58/SIRPB1 ratio | GCST90313855 | 3.37e-05 |
| 11332 | Omega-3 fatty acids to Omega-6 fatty acids ratio | GCST90502414 | 3.37e-05 |
| 11333 | Severity of induration at injection site at the injection site after COVID-19 booster vaccination | GCST90454409 | 3.34e-05 |
| 11334 | End-diastolic bi-ventricular shape (principal component 2) | GCST90448481 | 3.31e-05 |
| 11335 | GIMAP7 levels | GCST90469345 | 3.31e-05 |
| 11336 | OSM levels | GCST90470133 | 3.31e-05 |
| 11337 | KLK10 levels | GCST90469696 | 3.29e-05 |
| 11338 | BDNF levels | GCST90468437 | 3.28e-05 |
| 11339 | GALNT5 levels | GCST90469298 | 3.28e-05 |
| 11340 | COX5B levels | GCST90468834 | 3.27e-05 |
| 11341 | Phospholipids to Total Lipids in Small VLDL percentage | GCST90499902 | 3.25e-05 |
| 11342 | DIABLO/VSIR ratio | GCST90314470 | 3.25e-05 |
| 11343 | TGFBR2/TNFRSF1A ratio | GCST90315918 | 3.24e-05 |
| 11344 | LRP11 levels | GCST90469796 | 3.24e-05 |
| 11345 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502555 | 3.23e-05 |
| 11346 | HTRA2 levels | GCST90469494 | 3.23e-05 |
| 11347 | LBR/MAD1L1 ratio | GCST90315295 | 3.22e-05 |
| 11348 | Platelet count | GCST90002358 | 3.20e-05 |
| 11349 | ENO1 levels | GCST90469109 | 3.20e-05 |
| 11350 | DCTN1/TRIAP1 ratio | GCST90314434 | 3.20e-05 |
| 11351 | BSG/IL12A_IL12B ratio | GCST90313532 | 3.19e-05 |
| 11352 | DNER levels | GCST90469019 | 3.17e-05 |
| 11353 | Omega-3 fatty acid levels | GCST90502423 | 3.16e-05 |
| 11354 | TFPI2 levels | GCST90470838 | 3.14e-05 |
| 11355 | GRAP2 levels | GCST90469399 | 3.13e-05 |
| 11356 | VLDL cholesterol levels | GCST90500196 | 3.13e-05 |
| 11357 | TNN levels | GCST90470927 | 3.13e-05 |
| 11358 | CLEC4D levels | GCST90468773 | 3.13e-05 |
| 11359 | DBI levels | GCST90468949 | 3.11e-05 |
| 11360 | LEG1 levels | GCST90469753 | 3.11e-05 |
| 11361 | Total fatty acid levels | GCST90502710 | 3.10e-05 |
| 11362 | FBLN2 levels | GCST90469193 | 3.09e-05 |
| 11363 | CHRDL1/SMOC2 ratio | GCST90314062 | 3.08e-05 |
| 11364 | Heel quantitative ultrasound index (QUI), direct entry (left) | Bone-densitometry of heel | UKBB00000322 | 3.07e-05 |
| 11365 | Heel bone mineral density (BMD) T-score, automated (left) | Bone-densitometry of heel | UKBB00000316 | 3.07e-05 |
| 11366 | T1 FreeSurfer BA rh BA4p exvivo area | GCST90385552 | 3.06e-05 |
| 11367 | ATRAID levels | GCST90468399 | 3.06e-05 |
| 11368 | GATD3 levels | GCST90469309 | 3.06e-05 |
| 11369 | Alkenylphosphatidylcholine (P-16:0/16:0) levels | GCST90025563 | 3.06e-05 |
| 11370 | X-17357 levels | GCST90200550 | 3.03e-05 |
| 11371 | CLEC1B/VTA1 ratio | GCST90314107 | 3.03e-05 |
| 11372 | Ratio of saturated fatty acids to total fatty acids | GCST90092981 | 3.02e-05 |
| 11373 | ICA1/YTHDF3 ratio | GCST90315113 | 3.02e-05 |
| 11374 | C1QA levels | GCST90468485 | 3.02e-05 |
| 11375 | CD46/NECTIN2 ratio | GCST90313832 | 3.01e-05 |
| 11376 | Red cell distribution width | GCST90002369 | 3.00e-05 |
| 11377 | white blood cell count (WBC, minimum, inv-norm transformed) | GCST90476457 | 3.00e-05 |
| 11378 | CD69/NFATC1 ratio | GCST90313879 | 2.99e-05 |
| 11379 | CD22/FCER2 ratio | GCST90313756 | 2.96e-05 |
| 11380 | ANXA4/LACTB2 ratio | GCST90313293 | 2.96e-05 |
| 11381 | Phospholipids in small HDL | GCST90499483 | 2.95e-05 |
| 11382 | PLCB2 levels | GCST90470255 | 2.95e-05 |
| 11383 | Gastro-oesophageal reflux disease | FING00000564 | 2.95e-05 |
| 11384 | BTC levels | GCST90468476 | 2.94e-05 |
| 11385 | Phospholipids to total lipids in very large HDL percentage (UKB data field 23629) | GCST90269726 | 2.93e-05 |
| 11386 | DSC2/SPINT1 ratio | GCST90314557 | 2.93e-05 |
| 11387 | Rotator cuff injury | GCST90044700 | 2.92e-05 |
| 11388 | T1 FreeSurfer DK lh precuneus volume | GCST90385680 | 2.92e-05 |
| 11389 | DDHD2 levels | GCST90468968 | 2.91e-05 |
| 11390 | CPXM1 levels | GCST90468849 | 2.90e-05 |
| 11391 | Sarcoidosis | GCST90503483 | 2.90e-05 |
| 11392 | Appendectomy | FING00000104 | 2.89e-05 |
| 11393 | EDAR/SPARC ratio | GCST90314588 | 2.89e-05 |
| 11394 | CDC37 levels | GCST90468665 | 2.88e-05 |
| 11395 | rfMRI amplitudes (ICA100 node 15) | GCST90004603 | 2.87e-05 |
| 11396 | PTPRZ1 levels | GCST90470388 | 2.86e-05 |
| 11397 | PIGR levels | GCST90470232 | 2.84e-05 |
| 11398 | GFRA3 levels | GCST90469330 | 2.83e-05 |
| 11399 | STK4 levels | GCST90470767 | 2.83e-05 |
| 11400 | PTX3 levels | GCST90470392 | 2.83e-05 |
| 11401 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 71) | GCST90320634 | 2.83e-05 |
| 11402 | rfMRI connectivity ICA-features 3 | GCST90006341 | 2.82e-05 |
| 11403 | KAZN levels | GCST90469666 | 2.81e-05 |
| 11404 | IDP T1 FAST ROIs R ventral striatum | GCST90002560 | 2.81e-05 |
| 11405 | MAMDC2 levels | GCST90469841 | 2.81e-05 |
| 11406 | neutrophil (absolute count, mean, inv-norm transformed) | GCST90475529 | 2.81e-05 |
| 11407 | LRG1 levels | GCST90469793 | 2.79e-05 |
| 11408 | PLXDC2 levels | GCST90470264 | 2.79e-05 |
| 11409 | CRELD2/F2R ratio | GCST90314254 | 2.79e-05 |
| 11410 | DTI TBSS FA Posterior thalamic radiation R | GCST90384408 | 2.79e-05 |
| 11411 | HBEGF/PDGFB ratio | GCST90315034 | 2.78e-05 |
| 11412 | DKK1/VTA1 ratio | GCST90314485 | 2.78e-05 |
| 11413 | Gestational [pregnancy-induced] hypertension | FING00000571 | 2.78e-05 |
| 11414 | CDON levels | GCST90468687 | 2.77e-05 |
| 11415 | KIFBP/LYN ratio | GCST90315246 | 2.77e-05 |
| 11416 | SDC1 levels | GCST90470558 | 2.77e-05 |
| 11417 | Anterior thigh muscle fat infiltration percentage | GCST90267351 | 2.77e-05 |
| 11418 | IGF1R levels | GCST90469524 | 2.75e-05 |
| 11419 | Conductive hearing loss (PheCode 389.2) | GCST90475912 | 2.75e-05 |
| 11420 | ICAM3/NOTCH1 ratio | GCST90315122 | 2.75e-05 |
| 11421 | APRT levels | GCST90468345 | 2.74e-05 |
| 11422 | Triglycerides to Total Lipids in Small LDL percentage | GCST90499726 | 2.74e-05 |
| 11423 | IMMT levels | GCST90469609 | 2.73e-05 |
| 11424 | ABHD14B/APRT ratio | GCST90313137 | 2.70e-05 |
| 11425 | GGCT levels | GCST90469334 | 2.70e-05 |
| 11426 | WNT9A levels | GCST90471079 | 2.68e-05 |
| 11427 | SUGT1/TBL1X ratio | GCST90315897 | 2.67e-05 |
| 11428 | Skin luminance | GCST90320257 | 2.66e-05 |
| 11429 | ARSA levels | GCST90468368 | 2.65e-05 |
| 11430 | X-21736 levels | GCST90200584 | 2.63e-05 |
| 11431 | PDCD1LG2 levels | GCST90470180 | 2.63e-05 |
| 11432 | DBNL/DNAJA2 ratio | GCST90314415 | 2.62e-05 |
| 11433 | Dermatophytosis (PheCode 110.1) | GCST90475561 | 2.62e-05 |
| 11434 | ADAM8 levels | GCST90468220 | 2.61e-05 |
| 11435 | MAX levels | GCST90469867 | 2.60e-05 |
| 11436 | TFRC levels | GCST90470840 | 2.60e-05 |
| 11437 | CSF3 levels | GCST90468886 | 2.57e-05 |
| 11438 | Psoriasis | GCST90019016 | 2.57e-05 |
| 11439 | C9 levels | GCST90468505 | 2.55e-05 |
| 11440 | IL12B levels | GCST90274798 | 2.55e-05 |
| 11441 | lymphocyte (fraction, maximum, inv-norm transformed) | GCST90475432 | 2.54e-05 |
| 11442 | ABL1/PDLIM7 ratio | GCST90313150 | 2.54e-05 |
| 11443 | TMPRSS5 levels | GCST90470893 | 2.53e-05 |
| 11444 | PTPN1/SCAMP3 ratio | GCST90315743 | 2.52e-05 |
| 11445 | Ganglion cell inner plexiform layer (GCIPL) thickness | GCST90014267 | 2.49e-05 |
| 11446 | CLEC1A/GPR37 ratio | GCST90314084 | 2.49e-05 |
| 11447 | CD244/TREML2 ratio | GCST90313767 | 2.49e-05 |
| 11448 | PRDX3 levels | GCST90470317 | 2.49e-05 |
| 11449 | LY96/ST6GAL1 ratio | GCST90315348 | 2.48e-05 |
| 11450 | ESM1 levels | GCST90469153 | 2.48e-05 |
| 11451 | Omega-6 fatty acids to total fatty acids percentage | GCST90502545 | 2.47e-05 |
| 11452 | TXNDC15 levels | GCST90470990 | 2.45e-05 |
| 11453 | EBAG9/MITD1 ratio | GCST90314566 | 2.45e-05 |
| 11454 | Triglycerides in HDL | GCST90497464 | 2.44e-05 |
| 11455 | AmygNuclei rh volume Accessory-Basal-nucleus | GCST90002660 | 2.44e-05 |
| 11456 | DNMBP/TJAP1 ratio | GCST90314521 | 2.43e-05 |
| 11457 | Monounsaturated fatty acids to total fatty acids percentage | GCST90502384 | 2.43e-05 |
| 11458 | NOTCH1/SEMA7A ratio | GCST90315545 | 2.42e-05 |
| 11459 | FCAR levels | GCST90469197 | 2.41e-05 |
| 11460 | GRN levels | GCST90469404 | 2.40e-05 |
| 11461 | Triglycerides to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90501091 | 2.37e-05 |
| 11462 | CLSTN2/MATN2 ratio | GCST90314143 | 2.37e-05 |
| 11463 | LGALS9 levels | GCST90469765 | 2.37e-05 |
| 11464 | DLL1/EFEMP1 ratio | GCST90314494 | 2.37e-05 |
| 11465 | DKK1/PTPN6 ratio | GCST90314478 | 2.37e-05 |
| 11466 | Left-hemisphere control network to right-hemisphere salience/ventral attention network white-matter structural connectivity | GCST90302748 | 2.33e-05 |
| 11467 | COMP/ICAM1 ratio | GCST90314189 | 2.33e-05 |
| 11468 | GM3 ganglioside (d18:1/24:0) levels | GCST90024729 | 2.33e-05 |
| 11469 | Otosclerosis | FING00001131 | 2.32e-05 |
| 11470 | Monocyte percentage of white cells | GCST004609 | 2.31e-05 |
| 11471 | SPINT1 levels | GCST90470727 | 2.31e-05 |
| 11472 | MOG levels | GCST90469929 | 2.30e-05 |
| 11473 | Nontoxic goitre/thyroid nodule | FING00000887 | 2.30e-05 |
| 11474 | Hepatomegaly (PheCode 573.3) | GCST90476092 | 2.30e-05 |
| 11475 | PAG1 levels | GCST90470147 | 2.29e-05 |
| 11476 | DRG2 levels | GCST90469039 | 2.29e-05 |
| 11477 | SDC4/SEMA4D ratio | GCST90315818 | 2.29e-05 |
| 11478 | neutrophil (fraction, minimum, inv-norm transformed) | GCST90475541 | 2.28e-05 |
| 11479 | Right ventricular ejection fraction | GCST90134591 | 2.28e-05 |
| 11480 | SNAP29/VEGFC ratio | GCST90315862 | 2.26e-05 |
| 11481 | Blood cell traits latent factor 8 (white cell) | GCST90559250 | 2.26e-05 |
| 11482 | CCL28 levels | GCST90468580 | 2.26e-05 |
| 11483 | KLK7 levels | GCST90469706 | 2.25e-05 |
| 11484 | CRTAM/KLRD1 ratio | GCST90314277 | 2.24e-05 |
| 11485 | Heel broadband ultrasound attenuation (right) | Bone-densitometry of heel | UKBB00000320 | 2.24e-05 |
| 11486 | Linoleic acid levels | GCST90502012 | 2.24e-05 |
| 11487 | Aspartate aminotransferase levels | GCST90018724 | 2.23e-05 |
| 11488 | CDH5/ENG ratio | GCST90313954 | 2.23e-05 |
| 11489 | CKAP4/PGF ratio | GCST90314075 | 2.23e-05 |
| 11490 | NPDC1/PTGDS ratio | GCST90315549 | 2.23e-05 |
| 11491 | CD200R1 levels | GCST90468605 | 2.23e-05 |
| 11492 | MSR1 levels | GCST90469950 | 2.22e-05 |
| 11493 | PGLYRP1 levels | GCST90470219 | 2.22e-05 |
| 11494 | ANXA4 levels | GCST90468319 | 2.21e-05 |
| 11495 | Low hand grip strength (60 years and older) (EWGSOP) | GCST90007527 | 2.21e-05 |
| 11496 | CSF2RB levels | GCST90468883 | 2.20e-05 |
| 11497 | Migraine with aura | FING00000819 | 2.20e-05 |
| 11498 | White blood cell count | GCST90025985 | 2.20e-05 |
| 11499 | FABP1/SULT2A1 ratio | GCST90314755 | 2.20e-05 |
| 11500 | Malignant melanoma, excluding all cancers (controls excluding all cancers) | FING00000750 | 2.18e-05 |
| 11501 | NOTCH3/PTPRS ratio | GCST90315547 | 2.18e-05 |
| 11502 | MIF levels | GCST90469906 | 2.17e-05 |
| 11503 | FST/FSTL3 ratio | GCST90314882 | 2.17e-05 |
| 11504 | DSC2/EFEMP1 ratio | GCST90314555 | 2.17e-05 |
| 11505 | CD5/TNFRSF9 ratio | GCST90313862 | 2.17e-05 |
| 11506 | FLT4/ICAM2 ratio | GCST90314860 | 2.17e-05 |
| 11507 | KLK11 levels | GCST90469697 | 2.16e-05 |
| 11508 | Lymphocyte percentage (UKB data field 30180) | GCST90468083 | 2.16e-05 |
| 11509 | Red blood cell erythrocyte count (UKB data field 30010) | GCST90468098 | 2.16e-05 |
| 11510 | CD63 levels | GCST90468642 | 2.16e-05 |
| 11511 | Aspartate aminotransferase levels | GCST90278618 | 2.15e-05 |
| 11512 | Coronary angioplasty | FING00000357 | 2.14e-05 |
| 11513 | IL12A_IL12B/LAG3 ratio | GCST90315147 | 2.13e-05 |
| 11514 | PDLIM7/PLA2G4A ratio | GCST90315637 | 2.12e-05 |
| 11515 | CXCL6 levels | GCST90468933 | 2.12e-05 |
| 11516 | IGSF8/NECTIN2 ratio | GCST90315140 | 2.11e-05 |
| 11517 | FCRL6/GZMA ratio | GCST90314806 | 2.11e-05 |
| 11518 | CD48 levels | GCST90468635 | 2.10e-05 |
| 11519 | Mean platelet volume | GCST004599 | 2.10e-05 |
| 11520 | TPSAB1 levels | GCST90470951 | 2.10e-05 |
| 11521 | ITGA5/VCAM1 ratio | GCST90315206 | 2.09e-05 |
| 11522 | ERBB2 levels | GCST90469139 | 2.09e-05 |
| 11523 | TIMP1 levels | GCST90470869 | 2.09e-05 |
| 11524 | Neutrophils and lymphocytes in blood (confirmatory factor analysis Factor 35) | GCST90309369 | 2.08e-05 |
| 11525 | Red blood cell count | GCST90002403 | 2.07e-05 |
| 11526 | BACH1/PDLIM7 ratio | GCST90313445 | 2.07e-05 |
| 11527 | DBI/EDAR ratio | GCST90314408 | 2.06e-05 |
| 11528 | lymphocyte (fraction, mean, inv-norm transformed) | GCST90475435 | 2.06e-05 |
| 11529 | Left ventricular wall thickness (mean) | GCST90435264 | 2.05e-05 |
| 11530 | Left ventricular wall thickness (maximal) | GCST90435263 | 2.05e-05 |
| 11531 | GALNT10 levels | GCST90469295 | 2.05e-05 |
| 11532 | TNFRSF8/TNFRSF9 ratio | GCST90315940 | 2.02e-05 |
| 11533 | PDLIM7/TBC1D23 ratio | GCST90315640 | 2.02e-05 |
| 11534 | Phospholipids to Total Lipids in Medium VLDL percentage | GCST90499043 | 2.01e-05 |
| 11535 | Free Cholesterol in VLDL | GCST90500221 | 2.01e-05 |
| 11536 | FCRL5 levels | GCST90469208 | 2.00e-05 |
| 11537 | ANPEP/CXADR ratio | GCST90313272 | 2.00e-05 |
| 11538 | EDAR/TACC3 ratio | GCST90314589 | 1.99e-05 |
| 11539 | IRAK1/NFATC1 ratio | GCST90315194 | 1.99e-05 |
| 11540 | Average diameter for HDL particles (UKB data field 23433) | GCST90269530 | 1.99e-05 |
| 11541 | CD40/IGSF8 ratio | GCST90313815 | 1.99e-05 |
| 11542 | TMEM25 levels | GCST90470888 | 1.98e-05 |
| 11543 | Bone marrow fat fraction of thoracic vertebra 12 | GCST90652384 | 1.97e-05 |
| 11544 | CA4/TNFSF12 ratio | GCST90313589 | 1.97e-05 |
| 11545 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 40) | GCST90320859 | 1.97e-05 |
| 11546 | Breast cancer | GCST90018579 | 1.97e-05 |
| 11547 | Cholesterol_[M+H-H2O]1+ levels | GCST90060133 | 1.97e-05 |
| 11548 | Ulcerative colitis (strict definition, require KELA, min 2 HDR) | FING00001388 | 1.96e-05 |
| 11549 | Polyarthropathies | FING00001180 | 1.95e-05 |
| 11550 | LGALS8 levels | GCST90469764 | 1.95e-05 |
| 11551 | Triacylglycerol_58:7_[M+NH4]1+ levels | GCST90060564 | 1.94e-05 |
| 11552 | PDGFB/PRKAR1A ratio | GCST90315624 | 1.94e-05 |
| 11553 | CLEC14A/PIK3IP1 ratio | GCST90314080 | 1.93e-05 |
| 11554 | STK24 levels | GCST90470766 | 1.93e-05 |
| 11555 | Maximum carotid IMT (intima-medial thickness) at 210 degrees | Carotid ultrasound | UKBB00000428 | 1.92e-05 |
| 11556 | NECTIN2/SPON2 ratio | GCST90315530 | 1.92e-05 |
| 11557 | Phosphate | Blood biochemistry | UKBB00000644 | 1.92e-05 |
| 11558 | MMP9/PLTP ratio | GCST90315471 | 1.92e-05 |
| 11559 | triglyceride (minimum, inv-norm transformed) | GCST90476439 | 1.92e-05 |
| 11560 | CNST/ITGB1BP2 ratio | GCST90314158 | 1.92e-05 |
| 11561 | SMAD5 levels | GCST90470678 | 1.90e-05 |
| 11562 | LILRA2 levels | GCST90469771 | 1.90e-05 |
| 11563 | PLXNA4/SRPK2 ratio | GCST90315688 | 1.90e-05 |
| 11564 | Crohn's disease | GCST90475318 | 1.89e-05 |
| 11565 | VSIG10 levels | GCST90471050 | 1.87e-05 |
| 11566 | Polyunsaturated fatty acids to monounsaturated fatty acids ratio | GCST90502566 | 1.87e-05 |
| 11567 | CLEC1B/VSIR ratio | GCST90314106 | 1.87e-05 |
| 11568 | CA6/DNER ratio | GCST90313594 | 1.86e-05 |
| 11569 | Osteoporosis (PheCode 743.1) | GCST90476259 | 1.86e-05 |
| 11570 | White blood cell count | GCST90018758 | 1.85e-05 |
| 11571 | MARCO levels | GCST90469861 | 1.85e-05 |
| 11572 | RAD23B levels | GCST90470418 | 1.84e-05 |
| 11573 | Concentration of VLDL particles | GCST90500246 | 1.84e-05 |
| 11574 | DNAJB1/EIF4B ratio | GCST90314508 | 1.83e-05 |
| 11575 | COMP/DPP4 ratio | GCST90314188 | 1.83e-05 |
| 11576 | Monounsaturated fatty acid levels | GCST90502358 | 1.83e-05 |
| 11577 | VASP levels | GCST90471028 | 1.83e-05 |
| 11578 | CRH levels | GCST90468862 | 1.82e-05 |
| 11579 | Phospholipids in large VLDL | GCST90498243 | 1.81e-05 |
| 11580 | BTN2A1 levels | GCST90468480 | 1.81e-05 |
| 11581 | Saturated fatty acids levels | GCST90502658 | 1.81e-05 |
| 11582 | AmygNuclei rh volume Whole-amygdala | GCST90002667 | 1.80e-05 |
| 11583 | THPO levels | GCST90470857 | 1.80e-05 |
| 11584 | CR1 levels | GCST90468851 | 1.80e-05 |
| 11585 | RTBDN levels | GCST90470505 | 1.79e-05 |
| 11586 | F11R/GP1BA ratio | GCST90314722 | 1.78e-05 |
| 11587 | Phospholipids in large HDL (UKB data field 23560) | GCST90269657 | 1.78e-05 |
| 11588 | EDAR/TMSB10 ratio | GCST90314590 | 1.75e-05 |
| 11589 | PFKFB2 levels | GCST90470215 | 1.74e-05 |
| 11590 | Neutrophil count | GCST90025977 | 1.74e-05 |
| 11591 | AXL/MSR1 ratio | GCST90313422 | 1.73e-05 |
| 11592 | CRIM1 levels | GCST90468863 | 1.73e-05 |
| 11593 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T110 | ECGU000110 | 1.70e-05 |
| 11594 | NUDT5/TXNRD1 ratio | GCST90315582 | 1.70e-05 |
| 11595 | CTF1 levels | GCST90468901 | 1.70e-05 |
| 11596 | MANSC1/PODXL ratio | GCST90315372 | 1.70e-05 |
| 11597 | Plateletcrit | GCST90002400 | 1.68e-05 |
| 11598 | MDGA1 levels | GCST90469875 | 1.67e-05 |
| 11599 | Malignant neoplasm of oesophagus, excluding all cancers (controls excluding all cancers) | FING00000766 | 1.66e-05 |
| 11600 | ASS1 levels | GCST90468380 | 1.66e-05 |
| 11601 | Osteoporosis NOS (PheCode 743.11) | GCST90476260 | 1.66e-05 |
| 11602 | neutrophil (fraction, maximum, inv-norm transformed) | GCST90475535 | 1.66e-05 |
| 11603 | Alanine levels (UKB data field 23460) | GCST90269557 | 1.64e-05 |
| 11604 | IDP dMRI TBSS MO Pontine crossing tract | GCST90003953 | 1.63e-05 |
| 11605 | CD22/CD79B ratio | GCST90313755 | 1.62e-05 |
| 11606 | Heel broadband ultrasound attenuation (left) | Bone-densitometry of heel | UKBB00000319 | 1.62e-05 |
| 11607 | GPR37 levels | GCST90469397 | 1.62e-05 |
| 11608 | Total protein levels | GCST90468105 | 1.61e-05 |
| 11609 | Mean platelet thrombocyte volume (UKB data field 30100) | GCST90468087 | 1.61e-05 |
| 11610 | DTI TBSS L3 Anterior corona radiata L | GCST90384547 | 1.61e-05 |
| 11611 | ADGRE2 levels | GCST90468237 | 1.61e-05 |
| 11612 | AXL/CD163 ratio | GCST90313418 | 1.59e-05 |
| 11613 | Lymphocyte percentage of white cells | GCST004632 | 1.59e-05 |
| 11614 | Monocyte count | GCST004625 | 1.58e-05 |
| 11615 | Hereditary corneal dystrophies | FING00000611 | 1.58e-05 |
| 11616 | DTI TBSS L1 External capsule L | GCST90384461 | 1.58e-05 |
| 11617 | CD163/MARCO ratio | GCST90313737 | 1.57e-05 |
| 11618 | ENO3 levels | GCST90469111 | 1.57e-05 |
| 11619 | CD40/CRELD2 ratio | GCST90313811 | 1.56e-05 |
| 11620 | EDAR/SNAP23 ratio | GCST90314587 | 1.56e-05 |
| 11621 | PPBP levels | GCST90470289 | 1.56e-05 |
| 11622 | TEK levels | GCST90470829 | 1.55e-05 |
| 11623 | high density lipoprotein cholesterol (HDLC, maximum, inv-norm transformed) | GCST90475348 | 1.54e-05 |
| 11624 | KYNU/SCLY ratio | GCST90315265 | 1.54e-05 |
| 11625 | CD58/MEGF10 ratio | GCST90313853 | 1.54e-05 |
| 11626 | white blood cell count (WBC, maximum, inv-norm transformed) | GCST90476451 | 1.53e-05 |
| 11627 | neutrophil (absolute count, maximum, inv-norm transformed) | GCST90475526 | 1.53e-05 |
| 11628 | TNFRSF10C levels | GCST90470901 | 1.53e-05 |
| 11629 | Total protein levels | UKBB00000826 | 1.53e-05 |
| 11630 | SORT1 levels | GCST90470710 | 1.52e-05 |
| 11631 | IMPA1 levels | GCST90469610 | 1.50e-05 |
| 11632 | Cholesteryl Esters to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500958 | 1.50e-05 |
| 11633 | Triglycerides | GCST000758 | 1.49e-05 |
| 11634 | VNN2 levels | GCST90471044 | 1.48e-05 |
| 11635 | DTI TBSS MD Fornix | GCST90384577 | 1.48e-05 |
| 11636 | Plasma N-acetyltaurine levels in chronic kidney disease | GCST90265600 | 1.48e-05 |
| 11637 | VSIG4 levels | GCST90471052 | 1.47e-05 |
| 11638 | Monounsaturated fatty acids to total fatty acids percentage | GCST90499109 | 1.46e-05 |
| 11639 | PPP1R2/TACC3 ratio | GCST90315719 | 1.46e-05 |
| 11640 | Total Phosphatidylcholine levels | GCST90025204 | 1.45e-05 |
| 11641 | MAVS/TBL1X ratio | GCST90315399 | 1.45e-05 |
| 11642 | PLXNB3 levels | GCST90470267 | 1.45e-05 |
| 11643 | AAMDC levels | GCST90468186 | 1.44e-05 |
| 11644 | 1-ribosyl-imidazoleacetate levels | GCST90199815 | 1.44e-05 |
| 11645 | Total testosterone levels | GCST90012112 | 1.43e-05 |
| 11646 | SLAMF7/TXNDC15 ratio | GCST90315850 | 1.42e-05 |
| 11647 | SIRT2 levels | GCST90470642 | 1.42e-05 |
| 11648 | Concentration of medium VLDL particles | GCST90499016 | 1.41e-05 |
| 11649 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502166 | 1.41e-05 |
| 11650 | CEACAM19 levels | GCST90468691 | 1.41e-05 |
| 11651 | PSG1 levels | GCST90470353 | 1.41e-05 |
| 11652 | IL6R levels | GCST90469602 | 1.41e-05 |
| 11653 | CLEC14A levels | GCST90468766 | 1.41e-05 |
| 11654 | LGALS8/SOD2 ratio | GCST90315320 | 1.40e-05 |
| 11655 | Deep bite | FING00000380 | 1.40e-05 |
| 11656 | rfMRI connectivity (ICA100 edge 1099) | GCST90005952 | 1.40e-05 |
| 11657 | red blood cell count (RBC, mean, inv-norm transformed) | GCST90476349 | 1.40e-05 |
| 11658 | NELL2 levels | GCST90470027 | 1.39e-05 |
| 11659 | MYOC/NOTCH3 ratio | GCST90315507 | 1.38e-05 |
| 11660 | MZB1 levels | GCST90469987 | 1.38e-05 |
| 11661 | ITGA11 levels | GCST90469633 | 1.38e-05 |
| 11662 | Cheesecake liking | GCST90094730 | 1.38e-05 |
| 11663 | Bifidobacterium catenulatum abundance in stool | GCST90032224 | 1.38e-05 |
| 11664 | ALCAM/CNTN1 ratio | GCST90313235 | 1.38e-05 |
| 11665 | DDR1 levels | GCST90468970 | 1.37e-05 |
| 11666 | MGMT levels | GCST90469902 | 1.36e-05 |
| 11667 | CPA4 levels | GCST90468838 | 1.36e-05 |
| 11668 | CRYGD levels | GCST90468876 | 1.35e-05 |
| 11669 | FCRL5/ICAM3 ratio | GCST90314802 | 1.35e-05 |
| 11670 | Lung cancer | GCST90018655 | 1.35e-05 |
| 11671 | Glutamine levels | GCST90497282 | 1.34e-05 |
| 11672 | Basophil count | GCST90025997 | 1.34e-05 |
| 11673 | Allergic asthma (mode) | FING00000066 | 1.33e-05 |
| 11674 | PPP3R1 levels | GCST90470307 | 1.32e-05 |
| 11675 | PCDH9 levels | GCST90470172 | 1.32e-05 |
| 11676 | FCGR2B levels | GCST90469201 | 1.32e-05 |
| 11677 | BACH1/HEXIM1 ratio | GCST90313440 | 1.32e-05 |
| 11678 | SCGB1A1 levels | GCST90470540 | 1.31e-05 |
| 11679 | CLEC6A levels | GCST90468777 | 1.30e-05 |
| 11680 | DTI TBSS L3 Fornix | GCST90384529 | 1.30e-05 |
| 11681 | NUCB2 levels | GCST90470101 | 1.29e-05 |
| 11682 | BST2/CEACAM1 ratio | GCST90313537 | 1.29e-05 |
| 11683 | ADA levels | GCST90468231 | 1.29e-05 |
| 11684 | Cholesteryl Esters to Total Lipids in Very Large VLDL percentage | GCST90500565 | 1.28e-05 |
| 11685 | KLK8/NECTIN4 ratio | GCST90315258 | 1.28e-05 |
| 11686 | PF4 levels | GCST90470211 | 1.28e-05 |
| 11687 | CCL15/CCL23 ratio | GCST90313681 | 1.28e-05 |
| 11688 | PTPRH levels | GCST90470382 | 1.27e-05 |
| 11689 | HSD17B14 levels | GCST90469483 | 1.27e-05 |
| 11690 | PLA2G4A levels | GCST90470248 | 1.27e-05 |
| 11691 | CCDC80/CCL27 ratio | GCST90313669 | 1.26e-05 |
| 11692 | CD83/HAVCR2 ratio | GCST90313904 | 1.26e-05 |
| 11693 | PTPRM levels | GCST90470384 | 1.26e-05 |
| 11694 | ITGB7 levels | GCST90469647 | 1.26e-05 |
| 11695 | Cardiovascular diseases (excluding rheumatic etc) | FING00000255 | 1.26e-05 |
| 11696 | CEP20 levels | GCST90468712 | 1.25e-05 |
| 11697 | IGDCC4 levels | GCST90469523 | 1.25e-05 |
| 11698 | Hypertensive heart disease (PheCode 401.21) | GCST90475925 | 1.25e-05 |
| 11699 | CD163/SIGLEC1 ratio | GCST90313739 | 1.23e-05 |
| 11700 | FUT8/PDGFA ratio | GCST90314890 | 1.23e-05 |
| 11701 | MXRA8 levels | GCST90469968 | 1.23e-05 |
| 11702 | GP6/HPCAL1 ratio | GCST90314963 | 1.23e-05 |
| 11703 | Diseases of male genital organs | FING00000426 | 1.22e-05 |
| 11704 | T1 FreeSurfer BA rh BA3b exvivo area | GCST90385550 | 1.21e-05 |
| 11705 | ITGB1BP2 levels | GCST90012058 | 1.21e-05 |
| 11706 | CD99/CD99L2 ratio | GCST90313923 | 1.21e-05 |
| 11707 | CD163/FOLR2 ratio | GCST90313734 | 1.21e-05 |
| 11708 | CD27/FCRL5 ratio | GCST90313772 | 1.19e-05 |
| 11709 | XCL1 levels | GCST90471081 | 1.19e-05 |
| 11710 | VCAM1 levels | GCST90471031 | 1.17e-05 |
| 11711 | BGN levels | GCST90468441 | 1.16e-05 |
| 11712 | Glycoprotein acetyls levels | GCST90092821 | 1.16e-05 |
| 11713 | lymphocyte (fraction, minimum, inv-norm transformed) | GCST90475438 | 1.14e-05 |
| 11714 | T1 FreeSurfer BA rh BA2 exvivo volume | GCST90385576 | 1.14e-05 |
| 11715 | ITGB1/VASN ratio | GCST90315232 | 1.13e-05 |
| 11716 | ENO2/PLXNA4 ratio | GCST90314665 | 1.12e-05 |
| 11717 | DTI autoptx L3 ifo l tract | GCST90385205 | 1.12e-05 |
| 11718 | DNAJA2/PLXNA4 ratio | GCST90314504 | 1.11e-05 |
| 11719 | FXN/TRIAP1 ratio | GCST90314899 | 1.10e-05 |
| 11720 | BACH1/CNST ratio | GCST90313436 | 1.10e-05 |
| 11721 | CD84/DKK1 ratio | GCST90313911 | 1.09e-05 |
| 11722 | NELL2/SEZ6L ratio | GCST90315536 | 1.08e-05 |
| 11723 | Free cholesterol in very large VLDL | GCST90500575 | 1.07e-05 |
| 11724 | Basophil count | GCST90002379 | 1.06e-05 |
| 11725 | Cholesteryl Esters in Small HDL | GCST90499382 | 1.06e-05 |
| 11726 | Cholesterol in Small HDL | GCST90499348 | 1.06e-05 |
| 11727 | Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500920 | 1.06e-05 |
| 11728 | FCGR2A levels | GCST90469200 | 1.06e-05 |
| 11729 | ICAM3/TNFRSF13B ratio | GCST90315124 | 1.05e-05 |
| 11730 | red blood cell count (RBC, maximum, inv-norm transformed) | GCST90476345 | 1.05e-05 |
| 11731 | DAB2/VASH1 ratio | GCST90314369 | 1.05e-05 |
| 11732 | WFDC12 levels | GCST90471073 | 1.05e-05 |
| 11733 | Lymphocyte percentage of white cells | GCST90002389 | 1.05e-05 |
| 11734 | SHBG levels | GCST90503315 | 1.04e-05 |
| 11735 | CCN3/PGF ratio | GCST90313722 | 1.04e-05 |
| 11736 | FGF21 levels | GCST90469222 | 1.03e-05 |
| 11737 | CPXM1/SPARC ratio | GCST90314222 | 1.03e-05 |
| 11738 | Gastric ulcer | GCST90270927 | 1.02e-05 |
| 11739 | LCN2 levels | GCST90469747 | 1.01e-05 |
| 11740 | DTI autoptx FA fmi tract | GCST90385123 | 1.01e-05 |
| 11741 | SELPLG levels | GCST90470568 | 1.01e-05 |
| 11742 | TIMP4 levels | GCST90470872 | 1.01e-05 |
| 11743 | STAMBP levels | GCST90470756 | 1.00e-05 |
| 11744 | neutrophil (fraction, mean, inv-norm transformed) | GCST90475538 | 9.90e-06 |
| 11745 | Congestive heart failure | GCST90475200 | 9.87e-06 |
| 11746 | SERPINB1/TMSB10 ratio | GCST90315830 | 9.84e-06 |
| 11747 | CD93 levels | GCST90468656 | 9.77e-06 |
| 11748 | HMBS/PKLR ratio | GCST90315063 | 9.75e-06 |
| 11749 | CD300C/HAVCR2 ratio | GCST90313789 | 9.74e-06 |
| 11750 | Gout, strict definition | FING00000588 | 9.71e-06 |
| 11751 | C1S levels | GCST90468494 | 9.71e-06 |
| 11752 | CALCOCO1/MAP3K5 ratio | GCST90313605 | 9.66e-06 |
| 11753 | VTA1 levels | GCST90471058 | 9.66e-06 |
| 11754 | Mean carotid IMT (intima-medial thickness) at 240 degrees | Carotid ultrasound | UKBB00000446 | 9.65e-06 |
| 11755 | HDLBP levels | GCST90087533 | 9.59e-06 |
| 11756 | N-acetyl-1-methylhistidine levels | GCST90200690 | 9.59e-06 |
| 11757 | Triglycerides to Total Lipids in Small VLDL percentage | GCST90499934 | 9.58e-06 |
| 11758 | aseg global volume WM-hypointensities | GCST90002604 | 9.56e-06 |
| 11759 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T114 | ECGU000114 | 9.50e-06 |
| 11760 | Urine 3-hydroxyindolin-2-one sulfate levels in chronic kidney disease | GCST90264508 | 9.49e-06 |
| 11761 | Triglycerides in medium LDL | GCST90498864 | 9.38e-06 |
| 11762 | CLU levels | GCST90468793 | 9.33e-06 |
| 11763 | Fractured/broken bones in last 5 years | Medical conditions | UKBB00000258 | 9.28e-06 |
| 11764 | HPCAL1/MPIG6B ratio | GCST90315073 | 9.24e-06 |
| 11765 | SIGLEC8 levels | GCST90470636 | 9.11e-06 |
| 11766 | ALB levels | GCST90475100 | 9.09e-06 |
| 11767 | SCARB2 levels | GCST90470535 | 9.08e-06 |
| 11768 | IL7 levels | GCST90469606 | 9.04e-06 |
| 11769 | Bone marrow fat fraction of thoracic vertebra 8 | GCST90652380 | 8.96e-06 |
| 11770 | Mean platelet volume during second trimester of pregnancy | GCST90302230 | 8.93e-06 |
| 11771 | LRRC37A2 levels | GCST90469802 | 8.91e-06 |
| 11772 | SERPINE1/VASH1 ratio | GCST90315836 | 8.91e-06 |
| 11773 | FOLR1 levels | GCST90469259 | 8.82e-06 |
| 11774 | NADK/S100A11 ratio | GCST90315513 | 8.73e-06 |
| 11775 | ITGB6 levels | GCST90469646 | 8.72e-06 |
| 11776 | CD163 levels | GCST90468600 | 8.72e-06 |
| 11777 | Cerebrospinal fluid 5-methylthioadenosine (MTA) levels | GCST90318216 | 8.70e-06 |
| 11778 | CXCL3 levels | GCST90468931 | 8.66e-06 |
| 11779 | high density lipoprotein cholesterol (HDLC, mean, inv-norm transformed) | GCST90475352 | 8.63e-06 |
| 11780 | Clonal haematopoiesis of indeterminate potential (with or without mosaic chromosomal alteration) | GCST90165267 | 8.51e-06 |
| 11781 | Degree of unsaturation | GCST90502752 | 8.51e-06 |
| 11782 | BCAM/CDH5 ratio | GCST90313469 | 8.50e-06 |
| 11783 | Other Crohn's disease | FING00000992 | 8.50e-06 |
| 11784 | VSNL1 levels | GCST90471054 | 8.49e-06 |
| 11785 | Concentration of very large VLDL particles | GCST90500628 | 8.42e-06 |
| 11786 | CACNB3 levels | GCST90468523 | 8.41e-06 |
| 11787 | wg rh intensity-contrast entorhinal | GCST90003832 | 8.39e-06 |
| 11788 | T1 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 73) | GCST90320636 | 8.37e-06 |
| 11789 | BMP10 levels | GCST90468452 | 8.36e-06 |
| 11790 | AGR3 levels | GCST90468254 | 8.35e-06 |
| 11791 | PDGFB/PTPN6 ratio | GCST90315625 | 8.34e-06 |
| 11792 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T221 | ECGU000221 | 8.29e-06 |
| 11793 | FYB1 levels | GCST90469284 | 8.28e-06 |
| 11794 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502592 | 8.23e-06 |
| 11795 | BCAM/SEMA7A ratio | GCST90313476 | 8.22e-06 |
| 11796 | Clonal haematopoiesis of indeterminate potential (ASXL1 mutation) | GCST90165259 | 8.12e-06 |
| 11797 | RNF146 levels | GCST90421479 | 8.03e-06 |
| 11798 | MANF/NCK2 ratio | GCST90315359 | 7.99e-06 |
| 11799 | Free cholesterol in small LDL | GCST90499620 | 7.99e-06 |
| 11800 | NADK/PXN ratio | GCST90315512 | 7.95e-06 |
| 11801 | Lymphocyte percentage | Blood count | UKBB00000412 | 7.94e-06 |
| 11802 | CRTAC1 levels | GCST90468870 | 7.90e-06 |
| 11803 | JAM2 levels | GCST90469659 | 7.81e-06 |
| 11804 | CD69/SNAP29 ratio | GCST90313887 | 7.77e-06 |
| 11805 | Nonalcoholic fatty liver disease | GCST90091033 | 7.73e-06 |
| 11806 | ARHGEF12/DECR1 ratio | GCST90313349 | 7.72e-06 |
| 11807 | ICAM3 levels | GCST90469500 | 7.64e-06 |
| 11808 | TMEM106A levels | GCST90470886 | 7.56e-06 |
| 11809 | GPI levels | GCST90469391 | 7.53e-06 |
| 11810 | Height decline (log-difference score) | GCST90565853 | 7.51e-06 |
| 11811 | LTBR/TNFRSF14 ratio | GCST90315340 | 7.47e-06 |
| 11812 | EFNA4 levels | GCST90469081 | 7.42e-06 |
| 11813 | Total lipids in medium VLDL | GCST90499004 | 7.40e-06 |
| 11814 | DAPP1 levels | GCST90468946 | 7.35e-06 |
| 11815 | LILRB4 levels | GCST90469778 | 7.32e-06 |
| 11816 | ADM levels | GCST90468246 | 7.29e-06 |
| 11817 | COL1A1 levels | GCST90468813 | 7.22e-06 |
| 11818 | Retinal nerve fibre layer (RNFL) thickness | GCST90014266 | 7.17e-06 |
| 11819 | IGFBP3 levels | GCST90469529 | 7.17e-06 |
| 11820 | FUS levels | GCST90469278 | 7.16e-06 |
| 11821 | LRP11/NECTIN2 ratio | GCST90315329 | 7.14e-06 |
| 11822 | High density lipoprotein cholesterol levels | GCST90278635 | 7.13e-06 |
| 11823 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502633 | 7.12e-06 |
| 11824 | TRIAP1 levels | GCST90470963 | 7.04e-06 |
| 11825 | ACAN levels | GCST90468196 | 7.00e-06 |
| 11826 | ALB levels | GCST90497101 | 6.94e-06 |
| 11827 | SUSD5 levels | GCST90470789 | 6.93e-06 |
| 11828 | Generalized epilepsy | FING00000567 | 6.92e-06 |
| 11829 | CD72 levels | GCST90468646 | 6.85e-06 |
| 11830 | CTHRC1 levels | GCST90468902 | 6.84e-06 |
| 11831 | SCAMP3/VPS53 ratio | GCST90315807 | 6.84e-06 |
| 11832 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T491 | ECGU000491 | 6.80e-06 |
| 11833 | CGREF1 levels | GCST90468735 | 6.80e-06 |
| 11834 | Aspartate aminotransferase levels (UKB data field 30650) | GCST90468063 | 6.76e-06 |
| 11835 | triglyceride (mean, inv-norm transformed) | GCST90476435 | 6.73e-06 |
| 11836 | GAL/PM20D1 ratio | GCST90314917 | 6.72e-06 |
| 11837 | MMP9/OSM ratio | GCST90315468 | 6.69e-06 |
| 11838 | CX3CL1/LAYN ratio | GCST90314325 | 6.64e-06 |
| 11839 | MAN2B2 levels | GCST90469844 | 6.62e-06 |
| 11840 | Alanine aminotransferase levels | GCST90018723 | 6.59e-06 |
| 11841 | CLEC1B/TXNDC5 ratio | GCST90314105 | 6.57e-06 |
| 11842 | KLRB1 levels | GCST90469709 | 6.55e-06 |
| 11843 | Ascites (non malignant) (PheCode 572) | GCST90476090 | 6.44e-06 |
| 11844 | VEGFC levels | GCST90471036 | 6.39e-06 |
| 11845 | GPC5 levels | GCST90469387 | 6.39e-06 |
| 11846 | Hemoglobin | GCST90278631 | 6.37e-06 |
| 11847 | PHACTR2 levels | GCST90470224 | 6.36e-06 |
| 11848 | PODXL2 levels | GCST90470279 | 6.35e-06 |
| 11849 | QPCT levels | GCST90470401 | 6.35e-06 |
| 11850 | Total lipids in small VLDL | GCST90499840 | 6.30e-06 |
| 11851 | IL12A or IL12B levels | GCST90469548 | 6.30e-06 |
| 11852 | Saturated fatty acids levels | GCST90499950 | 6.28e-06 |
| 11853 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T115 | ECGU000115 | 6.27e-06 |
| 11854 | CCL5 levels | GCST90468584 | 6.23e-06 |
| 11855 | DTI autoptx FA ilf l tract | GCST90385126 | 6.20e-06 |
| 11856 | CPVL levels | GCST90468848 | 6.19e-06 |
| 11857 | APRT/CD63 ratio | GCST90313334 | 6.09e-06 |
| 11858 | MPIG6B/SUSD1 ratio | GCST90315487 | 6.07e-06 |
| 11859 | SUSD2 levels | GCST90470787 | 6.03e-06 |
| 11860 | XRCC4 levels | GCST90471085 | 5.95e-06 |
| 11861 | Intracerebral hemorrhage | GCST90018650 | 5.88e-06 |
| 11862 | Triglycerides to Total Lipids in Medium VLDL percentage | GCST90499073 | 5.86e-06 |
| 11863 | AmygNuclei lh volume Cortical-nucleus | GCST90002654 | 5.84e-06 |
| 11864 | CXCL1 levels | GCST90468930 | 5.77e-06 |
| 11865 | MEGF10 levels | GCST90469882 | 5.75e-06 |
| 11866 | CEACAM5 levels | GCST90468696 | 5.73e-06 |
| 11867 | Triacylglycerol_49:3_[M+NH4]1+ levels | GCST90060443 | 5.72e-06 |
| 11868 | KIRREL2 levels | GCST90469690 | 5.72e-06 |
| 11869 | Polyunsaturated fatty acids to total fatty acids percentage | GCST90502644 | 5.70e-06 |
| 11870 | RARRES2/TFPI ratio | GCST90315760 | 5.69e-06 |
| 11871 | Follicular cysts of skin and subcutaneous tissue | FING00000547 | 5.64e-06 |
| 11872 | FAM20A levels | GCST90469185 | 5.54e-06 |
| 11873 | CNST levels | GCST90468801 | 5.53e-06 |
| 11874 | Omega-6 fatty acids to total fatty acids percentage | GCST90502540 | 5.49e-06 |
| 11875 | F2R/MPIG6B ratio | GCST90314732 | 5.49e-06 |
| 11876 | ITGB1/ITGB2 ratio | GCST90315225 | 5.49e-06 |
| 11877 | APP/PPP1R12A ratio | GCST90313330 | 5.48e-06 |
| 11878 | Endometriosis of rectovaginal septum and vagina | FING00000503 | 5.47e-06 |
| 11879 | Phospholipids to Total Lipids in Large VLDL percentage | GCST90498258 | 5.43e-06 |
| 11880 | CHIT1 levels | GCST90468744 | 5.41e-06 |
| 11881 | CLPS/PRSS2 ratio | GCST90314141 | 5.40e-06 |
| 11882 | CRTAM/LY9 ratio | GCST90314278 | 5.40e-06 |
| 11883 | PRSS27 levels | GCST90470342 | 5.40e-06 |
| 11884 | ACVRL1/SCARB2 ratio | GCST90313157 | 5.38e-06 |
| 11885 | EGF levels | GCST90469086 | 5.36e-06 |
| 11886 | NELL1 levels | GCST90470026 | 5.35e-06 |
| 11887 | Total lipid levels in chylomicrons and extremely large VLDL | GCST90500994 | 5.34e-06 |
| 11888 | B3GNT7 levels | GCST90468411 | 5.31e-06 |
| 11889 | PDGFB/SDC4 ratio | GCST90315626 | 5.29e-06 |
| 11890 | CASP8/PRDX6 ratio | GCST90313655 | 5.24e-06 |
| 11891 | ENO2/FXYD5 ratio | GCST90314659 | 5.23e-06 |
| 11892 | SIGLEC9 levels | GCST90470637 | 5.23e-06 |
| 11893 | CCL5/TFPI ratio | GCST90313708 | 5.23e-06 |
| 11894 | EDAR/LAT2 ratio | GCST90314582 | 5.19e-06 |
| 11895 | CLEC1B levels | GCST90468768 | 5.17e-06 |
| 11896 | CLEC1A levels | GCST90468767 | 5.09e-06 |
| 11897 | Illnesses of mother: Alzheimer's disease/dementia (UKB data field 20110_10) | GCST90042678 | 5.08e-06 |
| 11898 | HCLS1 levels | GCST90469437 | 5.08e-06 |
| 11899 | Diseases of liver | FING00000425 | 5.07e-06 |
| 11900 | LRRN1 levels | GCST90469806 | 5.03e-06 |
| 11901 | SFTPA2 levels | GCST90470613 | 5.00e-06 |
| 11902 | Squamous cell carcinoma (MTAG) | GCST90137412 | 4.99e-06 |
| 11903 | RNF5 levels | GCST90470488 | 4.96e-06 |
| 11904 | PSME2/RBKS ratio | GCST90315737 | 4.95e-06 |
| 11905 | CCL17 levels | GCST90468569 | 4.94e-06 |
| 11906 | TNFRSF1A/TNFRSF1B ratio | GCST90315937 | 4.92e-06 |
| 11907 | ADH4/SCLY ratio | GCST90313195 | 4.73e-06 |
| 11908 | Glycoprotein acetyls levels | GCST90497328 | 4.68e-06 |
| 11909 | Concentration of large VLDL particles | GCST90498226 | 4.67e-06 |
| 11910 | Right ventricular peak ejection rate | GCST90268120 | 4.67e-06 |
| 11911 | Phospholipids in VLDL | GCST90500266 | 4.63e-06 |
| 11912 | APLP1 levels | GCST90468330 | 4.60e-06 |
| 11913 | PKD1 levels | GCST90470240 | 4.59e-06 |
| 11914 | Bone marrow fat fraction of thoracic vertebra 11 | GCST90652383 | 4.57e-06 |
| 11915 | ADIPOQ levels | GCST90468245 | 4.56e-06 |
| 11916 | Triglycerides in large LDL | GCST90498076 | 4.53e-06 |
| 11917 | ERBIN levels | GCST90469142 | 4.51e-06 |
| 11918 | Mean platelet volume during the postpartum period | GCST90302233 | 4.51e-06 |
| 11919 | PPP1R14D levels | GCST90470303 | 4.47e-06 |
| 11920 | ITGAV levels | GCST90469639 | 4.47e-06 |
| 11921 | CRADD/EREG ratio | GCST90314236 | 4.44e-06 |
| 11922 | Maximum carotid IMT (intima-medial thickness) at 240 degrees | Carotid ultrasound | UKBB00000429 | 4.43e-06 |
| 11923 | AmygNuclei rh volume Medial-nucleus | GCST90002663 | 4.42e-06 |
| 11924 | DKK3 levels | GCST90468998 | 4.42e-06 |
| 11925 | PODXL levels | GCST90470280 | 4.39e-06 |
| 11926 | ROBO2/SCARF2 ratio | GCST90315784 | 4.37e-06 |
| 11927 | Total triglycerides levels | GCST90500140 | 4.33e-06 |
| 11928 | AXIN1/CALCOCO1 ratio | GCST90313402 | 4.31e-06 |
| 11929 | Basophil percentage of white cells | GCST90002380 | 4.29e-06 |
| 11930 | FIS1/PDGFB ratio | GCST90314830 | 4.26e-06 |
| 11931 | ICAM1/REG1A ratio | GCST90315114 | 4.25e-06 |
| 11932 | Basophill percentage | Blood count | UKBB00000087 | 4.21e-06 |
| 11933 | Disorders of orbit | FING00000449 | 4.20e-06 |
| 11934 | Pneumoconiosis due to other inorganic dusts | FING00001173 | 4.20e-06 |
| 11935 | Total lipids in large VLDL | GCST90498207 | 4.10e-06 |
| 11936 | NOTCH1 levels | GCST90470065 | 4.09e-06 |
| 11937 | Sarcoidosis | FING00001275 | 4.09e-06 |
| 11938 | CD48/SLAMF7 ratio | GCST90313842 | 4.05e-06 |
| 11939 | LAT2/SERPINB1 ratio | GCST90315279 | 4.02e-06 |
| 11940 | BCAN levels | GCST90468426 | 4.02e-06 |
| 11941 | FOXO1/NFATC1 ratio | GCST90314873 | 4.01e-06 |
| 11942 | Free Cholesterol to Total Lipids in Large VLDL percentage | GCST90498199 | 4.00e-06 |
| 11943 | Aspartate aminotransferase | Blood biochemistry | UKBB00000052 | 4.00e-06 |
| 11944 | Mean carotid IMT (intima-medial thickness) at 210 degrees | Carotid ultrasound | UKBB00000445 | 3.99e-06 |
| 11945 | CD84/GP1BA ratio | GCST90313913 | 3.96e-06 |
| 11946 | FLT3 levels | GCST90469251 | 3.93e-06 |
| 11947 | ADGRG1 levels | GCST90468240 | 3.91e-06 |
| 11948 | X-11786--methylcysteine levels | GCST90243654 | 3.90e-06 |
| 11949 | BTN2A1/SIGLEC1 ratio | GCST90313548 | 3.89e-06 |
| 11950 | MET/PTPRF ratio | GCST90315435 | 3.89e-06 |
| 11951 | Free cholesterol in medium LDL | GCST90498774 | 3.88e-06 |
| 11952 | Cholesterol to Total Lipids in Large VLDL percentage | GCST90498130 | 3.87e-06 |
| 11953 | SCARF1/SUSD1 ratio | GCST90315811 | 3.84e-06 |
| 11954 | Mucosal proctocolitis | FING00000841 | 3.82e-06 |
| 11955 | T2 brain MRIs Unsupervised Deep learning derived Imaging Phenotypes (dimension 101) | GCST90320920 | 3.78e-06 |
| 11956 | CCL14 levels | GCST90468566 | 3.78e-06 |
| 11957 | Omega-6 fatty acids levels | GCST90499170 | 3.76e-06 |
| 11958 | NFX1 levels | GCST90470041 | 3.70e-06 |
| 11959 | KLK6 levels | GCST90012008 | 3.69e-06 |
| 11960 | CSTB levels | GCST90012006 | 3.64e-06 |
| 11961 | Leucine levels | GCST90243405 | 3.61e-06 |
| 11962 | Free Cholesterol to Total Lipids in Chylomicrons and Extremely Large VLDL percentage | GCST90500983 | 3.58e-06 |
| 11963 | TACC3 levels | GCST90470797 | 3.55e-06 |
| 11964 | FCRL5/MZB1 ratio | GCST90314804 | 3.54e-06 |
| 11965 | Regional enteritis (PheCode 555.1) | GCST90476066 | 3.50e-06 |
| 11966 | CXCL16/NOTCH1 ratio | GCST90314339 | 3.48e-06 |
| 11967 | Polyunsaturated fatty acids to saturated fatty acids ratio | GCST90502581 | 3.47e-06 |
| 11968 | LAG3 levels | GCST90469727 | 3.45e-06 |
| 11969 | Neutrophil percentage of white cells | GCST004633 | 3.43e-06 |
| 11970 | POSTN levels | GCST90470288 | 3.41e-06 |
| 11971 | Neonatal jaundice (paternal effect) | GCST90435147 | 3.40e-06 |
| 11972 | ICAM1 levels | GCST90469498 | 3.38e-06 |
| 11973 | Diacylglycerol_38:5_[M+H-H2O]1+ levels | GCST90060200 | 3.38e-06 |
| 11974 | RWDD1/SUMF2 ratio | GCST90315795 | 3.37e-06 |
| 11975 | Alzheimer's disease (MTAG) | GCST90449058 | 3.34e-06 |
| 11976 | Cholesterol to Total Lipids in Very Large VLDL percentage | GCST90500542 | 3.34e-06 |
| 11977 | APRT/EREG ratio | GCST90313335 | 3.33e-06 |
| 11978 | Left hippocampal volume | GCST90267952 | 3.32e-06 |
| 11979 | SLC39A5 levels | GCST90470661 | 3.26e-06 |
| 11980 | Nontoxic nodular goiter | endocrine/metabolic | UKBB00000529 | 3.24e-06 |
| 11981 | AIFM1 levels | GCST90468268 | 3.15e-06 |
| 11982 | FCER1A levels | GCST90469198 | 3.15e-06 |
| 11983 | MED18/TBL1X ratio | GCST90315415 | 3.14e-06 |
| 11984 | Phospholipids to Total Lipids in Very Large VLDL percentage | GCST90500655 | 3.13e-06 |
| 11985 | CDKN1A/TACC3 ratio | GCST90313975 | 3.09e-06 |
| 11986 | TNFRSF4/TNFRSF8 ratio | GCST90315938 | 3.06e-06 |
| 11987 | CD69/SCARF1 ratio | GCST90313885 | 3.04e-06 |
| 11988 | LGALS8/VWF ratio | GCST90315322 | 3.03e-06 |
| 11989 | Dermatophytosis / Dermatomycosis (PheCode 110) | GCST90475560 | 3.02e-06 |
| 11990 | CCL22 levels | GCST90468574 | 3.01e-06 |
| 11991 | Electrocardiogram morphology (amplitude at temporal datapoints) unadjusted, T112 | ECGU000112 | 3.01e-06 |
| 11992 | Reticulocyte count | GCST90025972 | 2.99e-06 |
| 11993 | CD163/ICAM1 ratio | GCST90313735 | 2.95e-06 |
| 11994 | NECTIN2/TNFRSF14 ratio | GCST90315531 | 2.91e-06 |
| 11995 | Takes medication for congestive heart failure? | GCST90475201 | 2.90e-06 |
| 11996 | CXCL5 levels | GCST90468932 | 2.90e-06 |
| 11997 | HLA-E levels | GCST90469459 | 2.88e-06 |
| 11998 | CD200 levels | GCST90468606 | 2.88e-06 |
| 11999 | Omega-3 fatty acid levels | GCST90502422 | 2.84e-06 |
| 12000 | Omega-6 fatty acid levels | GCST90502103 | 2.83e-06 |